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Abstract
Depression is the most common psychiatric disorder in Huntington’s disease (HD) patients. In the general population,
women are more prone to develop depression and such susceptibility might be related to serotonergic dysregulation. There
is yet to be a study of sexual dimorphism in the development and presentation of depression in HD patients. We
investigated whether 8-week-old male and female R6/1 transgenic HD mice display depressive-like endophenotypes
associated with serotonergic impairments. We also studied the behavioral effects of acute treatment with sertraline. We
found that only female HD mice exhibited a decreased preference for saccharin as well as impaired emotionality-related
behaviors when assessed on the novelty-suppressed feeding test (NSFT) and the forced-swimming test (FST). The
exaggerated immobility time displayed by female HD in the FST was reduced by acute administration of sertraline. We also
report an increased response to the 5-HT1A receptor agonist 8-OH-DPAT in inducing hypothermia and a decreased 5-HT2A
receptor function in HD animals. While tissue levels of serotonin were reduced in both male and female HD mice, we found
that serotonin concentration and hydroxylase-2 (TPH2) mRNA levels were higher in the hippocampus of males compared to
female animals. Finally, the antidepressant-like effects of sertraline in the FST were blunted in male HD animals. This study
reveals sex-specific depressive-related behaviors during an early stage of HD prior to any cognitive and motor deficits. Our
data suggest a crucial role for disrupted serotonin signaling in mediating the sexually dimorphic depression-like phenotype
in HD mice.
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Introduction
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disorder caused by expansion of CAG repeats in exon 1
of the huntingtin gene. Clinical onset of HD is determined on the
basis of motor symptoms, however the pre-motor stages of the
disease are commonly associated with depression [1,2,3,4]
Mood disorders are one of the most prevalent causes of
disability worldwide and depression is diagnosed in women at
roughly twice the incidence of men in the general population [5,6].
While HD is an autosomal dominant condition that affects both
males and females, there is yet to be a study of sexual dimorphism
in the development and presentation of depression in HD patients.
However our recent findings in a HD mouse model suggest such
clinical investigation is warranted. One hypothesis addressing the
sexual dimorphism of depression involves the monoamine
neurotransmitter serotonin (5-HT) [7]. Clinical studies suggest
gender differences in the associations observed between psychiatric
disorders and functional polymorphisms of 5-HT transporter (5-
HTT) [8,9,10,11] and tryptophan hydroxylase-2 (TPH2) [12,13].
The 5-HT1A and 5-HT2 receptors are also of particular interest
with respect to both pathogenesis and antidepressant efficacy [14].
Major depression has been associated with increased 5-HT1A
autoreceptor density in the dorsal raphe nucleus and/or reduced
postsynaptic 5-HT1A/5-HT2 receptor function [15,16,17,18,19],
sometimes in a gender-specific manner [20]. Furthermore, the
desensitization of the 5-HT1A autoreceptor has been demonstrated
to be essential for enhanced 5-HT transmission following chronic
treatment with selective 5-HT reuptake inhibitors [21]. Finally, 5-
HT1A and/or 5-HT2 receptor abnormalities have been described
in different rodent models of mood disorders [22,23,24,25] and
HD [26,27,28].
The neurobiological basis for the increased incidence of
depression in HD remains unclear. Therefore, establishment and
validation of an animal model of HD with depression-like
behaviors will provide a valuable tool for understanding the
mechanisms of the condition as well as the preclinical development
of effective therapies. A depressive-like phenotype has recently
been observed in two different mouse models of HD [27,29].
However, these studies did not satisfactorily rule out potential
confounds associated with the locomotor/cognitive impairments
and did not functionally assess the possible mechanism(s)
underlying the depressive-like behaviors.
Using the R6/1 transgenic HD mice which express exon 1 of
the mutant human huntingtin gene, we recently revealed sex-specific
changes in relation to the effects of HD mutation [27,30]. On the
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22133basis of those findings, the current study sought to assess the
putative female-specific depression-like behaviors at 8 weeks of age
(prior to any cognitive and motor deficits that are observed from
12 and 15 weeks of age respectively in this transgenic line [31,32])
and further investigate the possible dysregulation of 5-HT
signaling in HD animals.
Results
Altered affective behaviors in female HD mice
Measuring the time of immobility in the forced-swimming test
(FST), we found overall effects of genotype (F(1,97)=11.7,
p,0.001) and treatment (F(1,97)=10.3, p,0.01) as well as a
significant interaction between sex and genotype (F(1,97)=6.36,
p,0.01). We also found a significant interaction between sex,
genotype and treatment with sertraline (F(1,97)=3.85, p,0.05).
Indeed compared to WT animals, only female HD mice exhibited
augmented immobility times (Fig. 1B). In addition, acute
administration of sertraline decreased the mean immobility times
of all groups (p,0.05) except for male HD mice (Fig. 1A).
A second cohort of mice was then used to study the effects of
acute sertraline on the tail-suspension test (TST) as a second
measure of depression-related behavior. Looking at time of
immobility, we found overall effects of sex (F(1,67)=7.35,
p,0.05) and treatment (F(1,67)=33.5, p,0.001) but no effect of
genotype (F(1,67)=2.16, p=0.15) nor any significant between
factors interactions. Indeed regardless of genotype, acute sertraline
decreased immobility times of both male (Fig. 1C) and female
(Fig. 1D) animals on the TST.
Anhedonia, defined as a decrease in the perceived pleasant or
rewarding properties of events, is a core symptom in depression
and can be assessed using the well-validated saccharin preference
test [33]. We found a significant interaction between sex and
genotype (F(1,44)=5.84, p,0.05) on saccharin preference (Fig. 2A).
Indeed compared to WT animals, only female HD mice exhibited
reduced saccharin preference (p,0.05). Interestingly there was an
overall effect of genotype (F(1,44)=12.3, p,0.01) on total fluid
intake (Fig. 2B), but no significant effect of sex or interactions.
In order to extend the study of the emotionality-related
behaviors, mice were exposed to the novelty-suppressed feeding
test (NSFT) in which we measured the latency of the animal to eat
in an aversive environment. This paradigm provides an anxiety-
related measure and has been shown to be sensitive to both
anxiolytics and chronic antidepressants [34]. Analyzing the latency
to feed (Fig. 3A), we found a significant effect of both sex
(F(1,55)=9.6, p,0.01) and genotype (F(1,55)=13.3, p,0.001) as
well as a significant interaction (F(1,55)=4.2, p,0.05). Since
latency data failed to pass the normality test (p,0.05, Shapiro-
Figure 1. Effect of sex, HD mutation and acute sertraline administration on immobility time in mice exposed to the forced-
swimming test (FST) and the tail suspension test (TST). (A) Analyzing FST performances we found no differences in immobility time (in sec)
between R6/1 (HD) and wild-type (WT) vehicle-injected male mice. Acute injection with sertraline (20 mg/kg, i.p.) decreased immobility time in male
WT mice but not HD animals. (B) Control (vehicle-injected) female HD mice exhibited augmented immobility time when compared to WT animals.
The behavioral deficit observed in HD mice was rescued by acute sertraline which also decreased immobility in WT female mice. Looking at
immobility time in mice exposed to TST, we found a significant effect of sertraline in both (C) male and (D) female animals without any effect or
interaction with the genotype. Values represent means (6 SEM) of n=8–15 mice per group. WT vs. HD: (*) p,0.05; Vehicle vs. sertraline20: (+)
p,0.05, (++)p ,0.01.
doi:10.1371/journal.pone.0022133.g001
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significant group difference (p,0.01, Kruskal Wallis test).
Compared to WT animals, only female HD mice exhibited
augmented time to feed (p,0.01, Mann-Whitney test). Our
observations were not due to altered appetite motivations since
there was no difference in the amount of food consumed after
NSFT (Fig. 3B).
Sex-specific increased 8-OH-DPAT-induced hypothermia
in female HD mice
We assessed the hypothermic response to the 5-HT1A receptor
agonist 8-OH-DPAT to evaluate 5-HT1A autoreceptor function in
vivo. The involvement of 5-HT1A autoreceptors in mediating the 8-
OH-DPAT-induced hypothermia is well-established in the mouse
[35] but also see [36,37]. There were no differences in baseline
temperatures between the sexes or genotypes prior to drug
administration (data not shown). Considering the change in body
temperature for 1 h post-injection (Figure 4), we found that acute
administration of 8-OH-DPAT significantly decreased rectal
temperatures in a dose-dependent manner in both male (Fig. 4A)
and female (Fig. 4B) mice compared to saline-treated animals
(treatment effect: F(2,116)=142, p,0.001). There were significant
effects of both sex (F(1,116)=6.48, p,0.05) and genotype
(F(1,116)=4.61, p,0.05) as well as significant interactions between
the 3 factors. Indeed 20–30 min following 8-OH-DPAT (0.3 mg/
kg) administration, only female HD mice exhibited an enhanced
hypothermia when compared to WT animals (p,0.05).
Functional analysis of 5-HT1A and 5-HT2 heteroreceptors
We assessed 5-HT1A post-synaptic receptor function in vivo, by
measuring the effect of the 5-HT1A receptor agonist 8-OH-DPAT
on the plasma corticosterone levels in both male and female
animals. Regardless of sex and genotype, the acute administration
of 8-OH-DPAT (0.3 mg/kg, s.c.) significantly increased cortico-
sterone levels (Fig. 5A & 5B). There was a significant overall drug
effect (F(1,38)=31.7, p,0.001) but no effect of sex or genotype.
Figure 2. Effect of sex and HD mutation on saccharin-preference test and total fluid intake. (A) We found a significant interaction
between sex and genotype (F(1,44)=5.84, p,0.05) on saccharin preference (expressed as % of total fluid intake). Indeed compared to WT animals, only
HD female mice exhibited reduced saccharin preference. (B) Interestingly looking at total fluid intake (expressed in mL), we revealed an overall effect
of genotype (F(1,44)=12.3, p,0.01) but no significant effect of sex or interactions. Values represent means (6 SEM) of n=8–14 mice per group. WT vs.
HD: (*) p,0.05, (**) p,0.01.
doi:10.1371/journal.pone.0022133.g002
Figure 3. Effect of sex and HD mutation on the novelty suppressed feeding test (NSFT). (A) Analyzing the time (expressed in sec) to
complete the task in the NSFT, we found a significant interaction between sex and genotype (F(1,55)=4.2, p,0.05). Indeed compared to WT animals,
only HD female mice exhibited greater delay to complete the NSFT. (B) Interestingly measuring the amount of food consumed after NSFT, we did not
find any effect of genotype (F(1,55)=1.7, p=0.19) or interaction with the sex (F(1,55)=0.39, p=0.54). Values represent means (6 SEM) of n=12–17 mice
per group. WT vs. HD: (***) p,0.001.
doi:10.1371/journal.pone.0022133.g003
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dose-dependently induced head-twitches that were reduced in
both male (Fig. 5C) and female (Fig. 5D) HD mice compared to
their respective WT control groups. There were significant effects
of genotype (F(1,61)=32.8, p,0.001) and treatment (F(1,61)=59.8,
p,0.001), but no effect of sex (F(1,61)=0.99, p=0.75).
Effect of the HD mutation on gene expression in the
raphe
Analyzing mRNA levels of several targets involved in serotonin
homeostasis (Figure 6), we found an overall significant effect of sex
and genotype for both 5-HTT (F(1,19)=8.9, p,0.01 and
F(1,19)=10.4, p,0.01 respectively) and TPH2 (F(1,19)=6.45,
p,0.05 and F(1,19)=9.9, p,0.01 respectively). Interestingly, there
were genotype-sex interactions for 5-HTT (F(1,19)=4.8, p,0.05)
and TPH2 (F(1,19)=5.1, p,0.05). Post-hoc analysis showed that
both 5-HTT and TPH2 mRNA levels were decreased in female
WT when compared to male WT (p,0.01). In addition, HD
mutation decreased both 5-HTT and TPH2 gene expression in
males only (p,0.01). In contrast, 5-HT1A receptor mRNA levels
(Fig. 6B) were not affected by either sex (F(1,19)=1.5, p.0.05) or
genotype (F(1,19)=1.0, p.0.05).
Tissue levels of serotonin and its metabolite in HD mice
In order to assess the effect of the HD mutation on the global
serotonergic activity, we measured the levels of serotonin (5-HT)
and its metabolite (5-HIAA) in several brain areas (Figure 7)
including hippocampus (panels A&B), cortex (panels C&D) and
striatum (panels E&F). In each of the three brain regions studied,
we found an overall effect of genotype for both 5-HT and 5-HIAA
tissue levels. Post-hoc tests revealed significant reductions of 5-HT
and/or 5-HIAA levels in HD tissue compared to WT mice in both
sexes. We also found a significant effect of sex analyzing both 5-
HT and 5-HIAA levels in hippocampus (F(1,23)=65.6, p,0.001
and F(1,23)=13.2, p,0.001, respectively) as well as striatal 5-HIAA
levels (F(1,23)=19.3, p,0.001). Indeed, in these two regions female
WT mice exhibited decreased 5-HIAA levels when compared to
control male animals. Interestingly, the 2-way ANOVA revealed
significant interaction between sex and genotype only for
hippocampal 5-HIAA levels (F(1,23)=4.58, p,0.05).
Discussion
Despite evidence of affective disorders in HD and the known
susceptibility of female to developing depression in the general
population, there has yet to be a study of sexual dimorphism in the
development and presentation of depression in HD patients.
We report here a sexually dimorphic depression-like phenotype
in the R6/1 HD mice at 8 weeks of age, prior to the development
of any motor and/or cognitive deficits which may have
confounded previous studies [27,29]. We found that latency to
eat food in the NSFT as well as immobility times in FST were both
specifically prolonged in female but not in male HD mice, and that
the acute administration of the SSRI sertraline corrected this latter
behavioral impairment. Indeed in the FST, acute injection with
sertraline significantly decreased the immobility time of HD
animals (when compared to the HD vehicle-injected group),
leading to similar FST performances as those displayed by WT
controls (vehicle-injected group). In contrast, the HD mutation did
not affect TST performance at 8 weeks of age, consistent with the
view that distinct neurochemical pathways mediate responses to
FST versus TST [27,38,39]. These TST results are in contrast
with a previous study [27] which reported a conflicted and
unexpected ‘‘anti-depressive’’ phenotype displayed by female HD
mice exposed to TST at 12 weeks of age, and support the
relevance of studying depression-like behaviors in HD at an earlier
stage of the disease. As an indicator of altered reward system
function, the female but not male HD mice displayed a decreased
preference for saccharin. This is the first report of such sex-specific
behavioral deficits in R6/1 HD mice, since Pang et al. (2009)
focused on behavioral tests modeling the experience of helpless-
ness. Because the diagnosis of a depressive episode requires that an
individual has chronically experienced at least 2 out of the 3 core
symptoms (according to the ICD-10 criteria: low mood, fatigue
and anhedonia), it is critical to used a broad battery of behavioral
tests to satisfactorily characterize a depressive-like phenotype in
mice. Collectively, our present findings support the well-estab-
lished gender differences in the vulnerability to depression
reported in general population [5,6]. Similar results have been
found in other animal models of depression [40,41] and female-
specific impairments have already been reported using other
rodent models of HD [42,43,44].
Figure 4. Effect of sex and HD mutation on 8-OH-DPAT-induced hypothermia. Acute injection with the 5-HT1A receptor agonist 8-OH-DPAT
(0.1 and 0.3 mg/kg, s.c.), decreased rectal temperatures in a dose-dependent manner in both (A) male and (B) female mice when compared to saline-
treated animals. However, only female HD mice exhibited an augmented response to the high dose of 8-OH-DPAT (0.3 mg/kg). The maximum
hypothermic response to 8-OH-DPAT was observed 20 min post-injection in both WT/HD male (23.6960.31 and 23.8560.35uC respectively) and
WT/HD female (22.8160.30 and 23.8860.36uC respectively, p,0.05). Values are expressed as change of temperature (uC) compared to baseline and
represent means (6 SEM) of n=8–14 mice per group. WT vs. HD: (*) p,0.05.
doi:10.1371/journal.pone.0022133.g004
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mice to the same extent as WT controls. A similar antidepressant
effect seemed to occur in male animals exposed to TST in which
both genotypes responded to the drug. In contrast, but consistent
with previous findings at 12 weeks of age [27], acute sertraline
elicited an antidepressant-like effect in WT but not HD male mice
in FST, once again suggesting distinct pathways for response to
FST versus TST. Sex-differences in response to sertraline have
been described in chronic depression, with women being more
likely to show a favorable response to SSRIs compared to men
[45]. Several targets have been proposed in mediating the
antidepressant-like effect of acute sertraline [46,47,48] and it
would be too simplistic to draw conclusions based on the
correlation between immobility times in FST and 5-HTT mRNA
levels within a unique brain region. Indeed, we found that WT
females had lower 5-HTT mRNA levels than WT males in the
raphe but still responded to acute sertraline (however we
previously reported no sex differences for hippocampal and
cortical 5-HTT expression, [27]). All together our findings suggest
that lower 5-HTT gene expression may be associated with
vulnerability to depression in female mice but could have opposite
effects on male animals. Similarly women and men carrying the
less transcriptionally efficient 5-HTTLPR short allele display
opposite responses to environmental stress factors, suggesting that
the molecular mechanisms underlying depression may differ
between sexes [8,10–11].
Another present finding which helps explain the female-specific
depression-related behaviors, is the enhanced hypothermic
response to the 5-HT1A receptor agonist 8-OH-DPAT in female
but not in male HD mice. The desensitization of the 5-HT1A
autoreceptor localized in the dorsal raphe nucleus (DRN) is
essential for enhancement of 5-HT transmission following chronic
SSRI treatment [21,49] and sex differences in the adaptive
regulation of the 5-HT1A receptor-mediated responses have been
previously observed in mice [50,51,52]. In mice, 8-OH-DPAT-
induced hypothermia seems to be mediated by somato-dendritic 5-
HT1A autoreceptors [35]. However some data suggest that the
model may be more complex [36,37] and that other receptor(s)
and/or region(s) might be involved. In that regard change in
mRNA levels was not consistent with the increased response to 5-
HT1A agonist we observed in female HD mice, however 5-HT1A
receptor protein or binding was not examined in this present study
and may not have necessarily changed in the same direction as the
mRNA levels. Additional experiments (e.g. GTPgammaS or
electrophysiology) would be required to assess the 5-HT1A
autoreceptor function specifically in the raphe.
Figure 5. In vivo assessment of 5-HT1A and 5-HT2 post-synaptic receptor function using 8-OH-DPAT-induced change of
corticosterone levels and DOI-induced head-twitches. Compared to paired-saline injected animals, administration of the 5-HT1A agonist 8-OH-
DPAT (0.3 mg/kg, s.c.) significantly increased corticosterone levels in both (A) male and (B) female mice, regardless of the genotype. In the DOI-
induced head-twitches experiment (bottom panel), there was a significant effect of genotype in both sexes. Indeed, the number of head-twitches
following DOI (1 mg/kg) were decreased in (C) HD male and (D) HD female mice when compared to WT animals. Values represent means (6 SEM) of
n=5–10 mice per group. Saline vs. DPAT0.3: (+)p ,0.05, (++)p ,0.01, (+++)p ,0.001 WT vs. HD: (*) p,0.05, (**) p,0.01, (***) p,0.001.
doi:10.1371/journal.pone.0022133.g005
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depression-like behavior was associated with an increased response
to 8-OH-DPAT and a global reduction of serotonergic transmis-
sion as suggested by the decreased tissue levels of serotonin (5-HT)
and its metabolite (5-HIAA) in various brain areas of HD animals.
The 5-HT and 5-HIAA deficits observed in our 8-week-old female
R6/1 HD mice are consistent with similar findings in the R6/2
model [53]. Interestingly in male HD mice, 5-HT concentration
was reduced only in the cortex although levels of 5-HIAA were
massively decreased in the three regions studied. These observa-
tions suggested an impaired serotonin turnover in male HD.
Detailed exploration of the enzymes involved in 5-HT catabolism
(e.g. monoamine oxidase, aldehyde dehydrogenease) would be
informative to address this matter. In addition, both hippocampal
serotonin content and TPH2 mRNA levels were higher in male
when compared to female mice. Whether such sex differences in
neurochemistry are the cause or the consequence of the reported
sex-dependent 5-HT1A autoreceptor dysregulation, is an impor-
tant point to address in the future to facilitate understanding of the
pathophysiology of depression.
Supersensitivity of 5-HT1A autoreceptors has already been
reported in other animal models of depression [22,24,54] but also
see ([55,56]). In addition, enhanced 5-HT1A autoreceptor function
has been associated with reduced serotonergic neurotransmission
(as a lower baseline firing rate of DRN 5-HT neurons) in several
models of depression [39,57] and a significant negative correlation
between serotonin synthesis and 5-HT1A binding potential has
been reported in healthy volunteers [58]. Interestingly, an
increased 5-HT1A receptor density has also been observed in the
DRN of depressed patients [18,59]. However, there exists
disagreement within the literature regarding the presence and
direction of 5-HT1A receptor abnormalities [15,60]. Interestingly,
a sensitization of 5-HT7 receptors in HD mice cannot be excluded
since the involvement of these receptors in 8-OH-DPAT-induced
hypothermia has been reported in mice [37]. In addition, selective
5-HT7 receptor antagonists have been recently proposed as a new
class of antidepressants [61]. Whether such an adaptive change
occurs in HD mice is an interesting question to be addressed in
future studies.
The brain serotonin deficits reported in our 8-week-old female
HD mice are more likely to be driven by the resultant increased 5-
HT1A receptor-mediated inhibitory feedback on serotonergic
neuronal firing than impairment in the synthesis process. Indeed
in females, we did not find any genotype effect on the gene
expression of TPH2, the rate-limiting enzyme in the biosynthesis
of 5-HT. However, this interpretation is limited by a possible floor
effect in female mice (which showed lower levels of mRNA relative
to males). In contrast, TPH2 mRNA levels were reduced in HD
male mice when compared with control animals, although 5-HT
concentrations were not affected by the mutation, at least in male
hippocampus and striatum. Male HD mice could possibly have
developed adaptive changes to counteract the TPH2 deficit.
Whether such adaptation(s) occur in a region-specific manner
would be an interesting question to address. Interestingly, recent
data suggest that differences in brain 5-HT synthesis may be larger
between healthy and depressed men that between healthy and
depressed women [62]. Consistent with our observations in WT
animals, it has been found that females had lower levels of mRNA
relative to males quantifying mRNA in post-mortem human brain
[63]. In addition, the mean rate of serotonin synthesis in healthy
males was found to be 50% higher than in normal females [64].
Interestingly, a sex-specific increased in Hypothalamic-pitui-
tary-adrenal (HPA) axis reactivity has been recently reported in
women with chronic major depressive disorder [65]. As well as an
increased levels of the stress hormone (corticosterone/cortisol) in
both R6/2 HD mice and late-stage HD patients [66]. We
therefore assessed the effect of 5-HT1A post-synaptic receptor
activation on corticosterone levels [52] in both male and female
HD mice. The similar 8-OH-DPAT-induced increase in cortico-
sterone in both WT and HD animals was unexpected given that
HD mice have been demonstrated to have decreased 5-HT1A
receptor density [28] and gene expression [27] in the hippocampus
and the cortex. However, it is possible that the hypothalamic 5-
HT1A receptors (involved in mediating corticosterone release) were
Figure 6. Gene expression of 5-HT transporter (5-HTT), 5-HT1A
receptor (5-HT1AR) and tryptophan hydroxylase-2 (TPH2) in
the raphe. Measuring mRNA levels of several genes encoding proteins
that regulate 5-HT homeostasis, we found significant genotype-sex
interactions for both mRNA levels of (A) 5-HTT and (B) TPH2 but not for
(C) 5-HT1AR gene expression. Both 5-HTT and TPH2 mRNA levels were
decreased in female WT when compared to male WT. In addition, HD
mutation decreased both 5-HTT and TPH2 gene expressions in male
only. Finally 5-HT1AR mRNA levels were not affected by either the sex or
the genotype. Values represent means (6 SEM) of n=5–6 mice per
group. WT vs. HD: (**) p,0.01. Male vs. female: (##)p ,0.01.
doi:10.1371/journal.pone.0022133.g006
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adaptive changes. This putative adaptation could be related to the
altered DPAT-induced hypothermia and the increased fluid intake
(previously observed in R6/2 HD mice [67]) we reported here.
Indeed, the hypothalamus is known to be involved in the
regulation of body temperature and water balance. Whether such
putative region-specific changes are link to the hypothalamic
capacity to regulated endocrine activity still need to be addressed.
Figure 7. Concentrations of 5-HT and 5-HIAA in brain tissue. Using the HPLC system, we measured the tissue levels of serotonin (5-HT) and its
metabolite 5-hydroxyindolacetic acid (5-HIAA) in several brain areas. Both 5-HT and 5-HIAA concentrations were decreased in the hippocampus (A/B),
the cortex (C/D) and the striatum (E/F) in female HD mice when compared to WT animals. Levels of 5-HIAA were also reduced in male HD. Finally, male
mice exhibited higher hippocampal tissue levels of both 5-HT and 5-HIAA when compared to female animals. 5-HT and 5-HIAA are expressed in ng/g
tissue. Values represent means (6 SEM) of n=6–8 mice per group. WT vs. HD: (*) p,0.05, (**) p,0.01, (***) p,0.001. Male vs. female: (##)p ,0.01.
doi:10.1371/journal.pone.0022133.g007
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function in HD animals. These data demonstrate that the HD
mutation disrupts 5-HT2 receptor responses, and could be
associated with previously described decreases of 5-HT2A/2C
receptors in models of HD [26,27]. However, even though such
alterations have been observed in other mouse models of
depression [68,69], the reduced 5-HT2 receptor function was
displayed by both male and female HD mice and could not
explain per se the female-specific depression-like behaviors.
Interestingly, variation in levels of 5-HTT expression has been
shown to be a source of changes in 5-HT2A receptor function [70].
In conclusion, we have found that the female-specific depression
phenotype of the R6/1 model is associated with decreased levels of
serotonin and its metabolite across various brain regions, which
are likely due to altered 5-HT1A receptor signaling as suggested by
the increased 8-OH-DPAT-induced hypothermia displayed only
by female HD mice. The identification of this specific molecular
abnormality presents as a novel target for the early treatment or
prevention of depression in HD. Finally even though male HD
animals did not display any impaired emotionality-related
behaviors, they shared some aspects of molecular dysfunction
with the female HD mice such as a decreased 5-HT2A receptor
function when compared to WT animals.
Materials and Methods
Ethics Statement
All experiments were performed in accordance with the
guidelines of the HFI Animal Ethics Committee (approval ID,
AEC #08-100) and the National Health and Medical Research
Council (NHMRC).
Animals
R6/1 transgenic hemizygote males [71] were originally
obtained from the Jackson Laboratory (Bar Harbor, ME, USA)
and bred with CBB6 (CBA6C57/B6) F1 females to establish the
R6/1 colony at the Howard Florey Institute (HFI). After weaning,
animals were grouped housed (4 mice per cage with 2 of each
genotype) and maintained on a 12 h light/dark cycle with access
to food and water ad libitum. To avoid any possible ‘‘litter effects’’,
we ensure that animals from each litter were represented in each
experimental condition using an appropriate randomization. All
experiments were performed on male and female wild-type (WT)
and R6/1 (HD) mice at 8 weeks of age and in accordance with the
guidelines of the HFI Animal Ethics Committee (approval ID,
AEC #08-100) and the National Health and Medical Research
Council (NHMRC). Each animal was only exposed to a unique
behavioral test.
Drugs
The 5-HT2A/C receptor agonist, 1-(2, 5-dimethoxy-4-odophe-
nyl)- 2-aminopropane ((6)DOI) and the 5-HT1A receptor agonist,
8-hydroxy-di-n-propylaminotetralin ((6)-8-OH-DPAT) were sup-
plied by Sigma (Aldrich, NSW, Australia).
Body Temperature
Core temperature was measured at ambient temperature of
2361uC in gently restrained mice using a thermocouple probe
(ID-Tech-Bioseb, France; 0.71 mm diameter).
Forced-Swimming Test (FST)
Mice were individually placed into a glass beaker (13 cm
diameter) filled with 12 cm deep water (25–26uC) and video
recorded for 300 secs. Total immobility time was manually scored
by an experienced experimenter blind to treatment and mouse
genotype. To study the effects of acute sertraline (Pfizer Inc, CT,
USA), mice were injected intraperitoneally (i.p.) with either vehicle
(1% Tween-20, 1 ml/100 g body weight) or sertraline (20 mg/kg)
60 mins before FST [27]. A total of 105 animals (48 males and 57
females) were assessed on FST (n=10–15 mice per group).
Tail-Suspension Test (TST)
Mice were suspended by the tail to a hook using adhesive tape.
The duration of immobility over a 6-min session was manually
scored by an experienced experimenter blind to treatment and
mouse genotype. To study the effects of acute sertraline (Pfizer Inc,
CT, USA), mice were injected intraperitoneally (i.p.) with either
vehicle (1% Tween-20, 1 ml/100 g body weight) or sertraline
(20 mg/kg) 30 mins before TST [27]. A total of 75 animals (41
males and 34 females) were assessed on TST (n=8–12 mice per
group).
Novelty-Suppressed Feeding Test (NSFT)
As previously described [27], mice were food deprived for 48-
hours prior to testing but allowed 2-hours of feeding after an initial
24-hour period. Water was available ad libitum. During the test, a
single food pellet was placed on a piece of filter paper in the centre
of the test arena (80680680 cm). Individual mice were then
placed into a corner of the arena and the latency to grasp and feed
on the food pellet within 5 minute was recorded. Upon the
initiation of feeding or reaching the time limit, mice were removed
and allowed to feed on a single food pellet of pre-determined
weight for 5 minutes (to assess the level of hunger). A total of 59
animals (29 males and 30 females) were assessed on NSFT (n=12–
17 mice per group).
Saccharin-preference test
Based on a validated protocol [33], single housed mice were
exposed to both 0.1% saccharin and tap water solutions across
four 15 h-overnight periods (18:00 h to 9:00 h). To avoid place
preference, the position of the 2 bottles was varied every day across
the left or right side of the feeding compartment. In order to take
into account time for the animals to become accustomed to the
testing environment, saccharin preference score (saccharin intake/
total fluid intake) was calculated as the mean of the 2 last
measures. A total of 48 animals (22 males and 26 females) were
assessed on saccharin preference test (n=8–14 mice per group).
8-OH-DPAT-induced hypothermia
As previously described [39], basal values were determined just
before subcutaneous injection of the 5-HT1A receptor agonist 8-
OH-DPAT (0.1 and 0.3 mg/kg) or vehicle (0.9% NaCl, 1 ml/
100 g body weight), and body temperature was measured every
10 min thereafter. The response to 8-OH-DPAT was calculated as
the decrease (from baseline) in body temperature during 60-min
post injection. A total of 128 animals (58 males and 70 females)
were used for 8-OH-DPAT-induced hypothermia (n=8–14 mice
per group).
8-OH-DPAT-induced change of serum corticosterone
levels
Mice naı ¨ve to behavioral testing were killed 60-min after acute
subcutaneous injection of the 5-HT1A receptor agonist 8-OH-
DPAT (0.3 mg/kg) or vehicle, between 8.30–10.00am. Blood was
collected, left to clot at room temperature for 30 mins and
centrifuged at 1000 g for 15 mins. Serum was then collected and
corticosterone quantified with an Enzyme Immuno Assay
PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22133(Cayman Chemical Company, Ann Arbor, MI, USA). A total of
46 animals (23 males and 23 females) were used for 8-OH-DPAT-
induced corticosterone release (n=5–7 mice per group).
DOI-induced Head-Twitches
Mice were administered with vehicle or the 5-HT2A/C receptor
agonist (6)DOI (0.3 and 1 mg/kg, i.p.) and immediately placed
inside an observation area. The number of head twitches was
counted for a 15-min period starting 15 min after drug
administration. A total of 69 animals (32 males and 37 females)
were used for DOI-induced head-twitches (n=8–10 mice per
group).
Real-time PCR for quantification of mRNA expression
Mice naı ¨ve to behavioral testing were killed for dissection of
raphe. Total RNA was isolated using Qiagen RNeasy extraction
kits (Qiagen, NSW, Australia) and stored at 280uC. RNA
concentration and quality were determined using Nanodrop
spectrophotometer. cDNA was reverse transcribed from 1 mg of
total RNA per sample using Applied Biosciences Reverse
Transcription kits (PE Applied Biosystems, Foster City, CA,
USA) with random hexamers. The reverse transcription PCR
conditions were 25uC—10 min, 48uC—30 min and 95uC—
5 min. cDNA products were stored at 220uC. Quantitative real-
time PCR was performed using SYBR Green PCR master mix
(Sigma-Aldrich) on a PE ABI Prism 7500 Light Cycler system (PE
Applied Biosystems). All primer pairs were optimized for working
concentrations before use and primer sequences are as follows.
Serotonin 1A receptor (5-HT1AR) F: CCC CAA CGA GTG CAC
CAT, R: GCG CCG AAA GTG GAG TAG AT; Serotonin
transporter (5-HTT) F: CTT CAG CCC CGG ATG GTT, R:
GTG GAC TCA TCA AAA AAC TGC AAA; TPH2 F: GAC
AAC GTG CCG CAA CTG R: TGA AGC CAG ATC GCT
CTT TCA; Cyclophilin F: CCC ACC GTG TTC TTC GAC A,
R: CCA GTG CTC AGA GCT CGA AA. Cyclophilin was used
as the endogenous housekeeping gene as it is not altered in the
R6/1 mouse line at this age (Zajac, unpublished data). Real-time
PCR conditions were 50uC—2 min, 95uC—10 min, followed by
40 cycles of 95uC—15 s and 60uC— 1 min. All reactions were
performed on five-eight individual subjects per group, each in
triplicate. Melt curve analyses were performed to ensure that only
one reaction product was obtained. A total of 23 animals (12 males
and 11 females) were used for gene expression analyses (n=5–6
mice per group).
Whole tissue measurements of 5-HT and its metabolite
Mice naı ¨ve to behavioral testing were killed for brain dissection.
Tissue levels of endogenous 5-HT and its metabolite 5-
hydroxyindolacetic acid (5-HIAA) were determined as previously
published [39]. Dissected brain structures were homogenized in 5–
10 volumes (v/w) of ice-cold 0.1 M HClO4 containing 1.34 mM
disodium EDTA and 0.05% Na2S2O5. Homogenates were
centrifuged at 30,000 g for 20 min at 4uC. After neutralization
with 2 M KH2PO4/K2HPO4, pH 7.4, containing 0.01 mg per
mL ascorbate oxidase (Boehringer Mannheim, Meylan, France),
supernatants were further centrifuged at 30,000 g for 20 min.
Aliquots (10 mL) of clear supernatants were injected into a high
performance liquid chromatography (HPLC) column (Ultrasphere
IP, Beckman, Gagny, France; 2560.46 cm, C18 reversed phase,
particle size 5 mm) protected with a Brownlee pre-column (3 cm,
5 mm). The mobile phase for the elution (at a flow rate of 1 mL per
min) consisted of (in mM): KH2PO4, 70; triethylamine, 3.1;
disodium EDTA, 0.1; octane sulphonate, 1.05; methanol, 16%,
adjusted to pH 3.02 with solide citric acid. The electrochemical
detection system (ESA 5011, Bedford, MA, USA) comprises an
analytical cell with dual coulometric monitoring electrodes (+50
and +350 mV). The generated signals were integrated by a
computing integrator (Millenium 32, Waters, Saint Quentin
Fallavier, France). A total of 27 animals (14 males and 13 females)
were used for HPLC analyses (n=6–8 mice per group).
Statistical Analysis
Analyses of variance (ANOVAs) were used to examine main
effects and/or interactions. A 2-way ANOVA was used to analyze
the effects of sex and genotype on saccharin preference, NSFT as
well as measurement of gene expression (qPCR) and serotonin
levels (HPLC). For the experiments involving pharmacological
treatments, the effects of sex, genotype and treatment(s) were
analyzed by a 3-way ANOVA. To determine specific group
differences in case of significant main effects (or interaction), the
ANOVAs were followed by Fisher’s LSD or Bonferroni post-hoc
tests. Since the latency data failed to pass the normality test
(Shapiro-Wilk), group differences in the NSFT were analyzed by
non-parametric tests (i.e. Kruskal Wallis test followed by a Mann-
Whitney test). In all cases, the significance level was set at p,0.05.
Statistical analyses were performed using SPSS statistics 17.0 and
Prism 5.
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